Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Caris Life Sciences (CAI) Gains from Investment Securities (2024 - 2025)

Caris Life Sciences has reported Gains from Investment Securities over the past 2 years, most recently at $740000.0 for Q4 2025.

Quarterly results put Gains from Investment Securities at $740000.0 for Q4 2025, up 2.07% from a year ago — trailing twelve months through Dec 2025 was $4.0 million (changed N/A YoY), and the annual figure for FY2025 was -$48000.0, down 106.62%.
Gains from Investment Securities for Q4 2025 was $740000.0 at Caris Life Sciences, up from $443000.0 in the prior quarter.
Over the last five years, Gains from Investment Securities for CAI hit a ceiling of $2.1 million in Q3 2024 and a floor of $443000.0 in Q3 2025.